Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 415

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 415
---
 S-4 filed on May 13, 2024 (Registration No. 333-279368))

     10.13††
     
    Asset Purchase Agreement, dated January 26, 2023, between TuHURA Biopharma Inc. and Morphogenesis, Inc. (incorporated by reference to Exhibit 10.40 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368))

     10.14
     
    Exclusivity and Right of First Offer Agreement, dated July 3, 2024, between TuHURA Biosciences, Inc. and Kineta, Inc. (incorporated by reference to Exhibit 10.41 to the Registration Statement on Form S-4/A filed on July 19, 2024 (Registration No. 333-279368)) 

     10.15
     
    Form of Secured Promissory Note (incorporated by reference to Exhibit 10.1 to the Registrant's Current  Report on Form    8-K filed on February 14, 2025)

    10.16
     
    Clinical Trial Funding Agreement, dated December 11, 2024, between TuHURA Biosciences, Inc. and Kineta, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on December 12, 2024)

    10.17#
     
    Form of TuHURA Biosciences, Inc. Stock Option Agreement under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on November 15, 2024)

    10.18#*
     
    TuHURA Biosciences, Inc. 2025 Non-Employee Director Compensation Program

    19.1*
     
    Insider Trading Policy

    21.1
     
    List of Subsidiaries (incorporated by reference to Exhibit 21.1 to TuHURA Biosciences, Inc’s Current Report on Form 8-K filed with the SEC on October 21, 2024)

    23.1*
     
    Consent of Cherry Bekaert LLP, independent registered public accounting firm. 

    31.1*